
BELGIUM - Gilde portfolio company Ablynx raises EUR 75m in Euronext Brussels
Gilde portfolio company Ablynx has raised EUR 75m in the largest biotech IPO on Euronext Brussels. The IPO was priced at EUR 7 per share. Pursuant to the offering, 10,714,285 new shares, equivalent to EUR 75m will be issued by Ablynx, and additionally, 1,607,142 over-allotment shares, equivalent to EUR11.25m will be allocated. If the over-allotment option is exercised in full, the total amount of the capital increase will amount to EUR 86.25m.
Latest News
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme
Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote
Permira to take Ergomed private for GBP 703m
Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO
Partners Group to release IMs for Civica sale in mid-September
Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017
Change of mind: Sponsors take to de-listing their own assets
EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater